Neither HER2-positive nor HER2-negative is universally “better.” The answer depends on which combination of breast cancer subtypes you’re comparing, because HER2 status intersects with hormone receptor (HR) status to create four distinct profiles, each with different survival rates and treatment options. The most common subtype, HR-positive/HER2-negative, has the highest five-year survival rate at 95.6%. But HER2-positive cancers, once considered the most dangerous, now have highly effective targeted therapies that have dramatically improved outcomes over the past two decades.
Four Subtypes, Not Two
Breast cancer isn’t simply HER2-positive or HER2-negative. It’s classified into four main subtypes based on two factors: whether the cancer has hormone receptors (for estrogen or progesterone) and whether it overproduces the HER2 protein. Each combination behaves differently and responds to different treatments.
Here are the five-year relative survival rates from the National Cancer Institute’s SEER database (2015-2021):
- HR-positive/HER2-negative: 95.6%
- HR-positive/HER2-positive: 91.8%
- HR-negative/HER2-positive: 86.5%
- HR-negative/HER2-negative (triple-negative): 78.4%
The best overall numbers belong to HR-positive/HER2-negative cancers, which are also the most common type. These cancers grow slowly, respond well to hormone-blocking treatments, and when caught at a localized stage have a five-year survival rate approaching 100%. At the other end, triple-negative breast cancer (negative for both hormone receptors and HER2) has the lowest survival rate because it lacks the specific targets that newer therapies can attack.
Why HER2-Positive Used to Be Worse
HER2 is a protein that promotes cell growth. When a cancer cell has too many copies of the HER2 gene, it produces excess protein on its surface, driving the cancer to grow and spread more aggressively. Before targeted treatments existed, HER2-positive cancers had a notably poor prognosis. Tumors grew faster, were more likely to invade lymph vessels, and recurred more often than HER2-negative cancers.
That changed in 2000 with the approval of the first targeted therapy designed to block HER2. This drug works by attaching to the HER2 protein on the cancer cell’s surface, shutting down the growth signals and flagging the cell for destruction by the immune system. The impact on survival was substantial, transforming HER2-positive cancer from one of the most feared subtypes into one with a strong treatment arsenal.
How Targeted Therapy Changed the Picture
The survival gains for HER2-positive patients have been striking. For patients with advanced HER2-positive cancer, median overall survival improved by about 11 months between 2008-2012 and 2013-2017 as newer targeted drugs became available. The improvement was especially dramatic for patients whose tumors were hormone receptor-negative and HER2-positive: their median survival jumped from 22.7 months to 40.9 months, a gain of over 18 months.
Today, there are multiple classes of HER2-targeted treatments. Some block the HER2 protein from sending growth signals. Others prevent HER2 from pairing with related proteins on the cell surface, cutting off an additional growth pathway. A newer class, called antibody-drug conjugates, essentially uses the HER2-targeting antibody as a delivery vehicle to carry a potent chemotherapy drug directly into the cancer cell, sparing healthy tissue from much of the damage. This precision is why HER2-positive patients now have options that HER2-negative patients don’t.
What HER2-Negative Patients Face
If your cancer is HER2-negative but hormone receptor-positive, you’re in the most favorable subtype statistically. Treatment typically involves hormone therapy, which blocks the hormones (estrogen or progesterone) that fuel the cancer’s growth. These medications are taken for years after initial treatment and are effective at preventing recurrence. When the cancer is localized, the five-year survival rate is essentially 100%. Even when it has spread to nearby lymph nodes, the rate is around 90%.
Triple-negative breast cancer is the most challenging subtype. Without hormone receptors or HER2 to target, treatment relies more heavily on traditional chemotherapy. However, this picture is evolving. A category called “HER2-low” has recently been defined for tumors that produce small amounts of HER2 protein, not enough to qualify as HER2-positive but enough to serve as a target. Roughly half of previously “HER2-negative” tumors actually fall into this HER2-low category, and newer antibody-drug conjugates have shown effectiveness against them. This has opened a treatment door for many patients who previously had fewer options.
Side Effects of Each Treatment Path
The treatment experience differs meaningfully between HER2-positive and HER2-negative patients. HER2-targeted therapies are more precise than traditional chemotherapy, which means they tend to cause a different, often more manageable set of side effects. The most common issues with targeted treatments are diarrhea (affecting about 29% of patients) and skin rash (about 22%). The majority of side effects are mild to moderate in severity.
One concern specific to HER2-targeted therapy is the heart. About 2% of patients in studies experienced cardiac events. This is monitored closely during treatment, usually with regular heart function tests. Traditional chemotherapy, used more often for HER2-negative cancers (especially triple-negative), brings the familiar side effects of nausea, hair loss, fatigue, and lowered immune function, though these vary widely depending on the specific drugs used.
Recurrence Patterns Differ by Subtype
HER2 status also affects when and where cancer is most likely to return. For patients with hormone receptor-positive tumors, the added risk from being HER2-positive tends to decrease over time. In other words, the difference between HER2-positive and HER2-negative narrows in the years after diagnosis. For bone metastases specifically, HER2-positive status actually becomes increasingly protective over time regardless of hormone receptor status.
For liver and distant lymph node spread, HER2-positive patients consistently show lower recurrence rates than HER2-negative patients. The picture is more complex for brain metastases: among hormone receptor-negative patients, HER2-positive status is initially associated with lower recurrence rates, but this advantage reverses after several years. This is one area where HER2-positive patients may face a distinct challenge, as HER2-positive cancers have a known tendency to spread to the brain.
The Bottom Line on “Better”
If you’re comparing the best-case scenario in each group, HR-positive/HER2-negative cancer has the highest survival rate at 95.6%. But if you’re comparing the worst-case scenarios, being HER2-positive is better than being triple-negative, because HER2 gives doctors a clear target to attack with multiple effective therapies. The 86.5% five-year survival rate for HR-negative/HER2-positive cancer is substantially higher than the 78.4% rate for triple-negative disease.
What matters most isn’t HER2 status alone but the full profile of your cancer, including hormone receptor status, stage at diagnosis, and grade. HER2-positive cancer, once the most aggressive subtype, now benefits from some of the most effective targeted treatments in oncology. And even patients with HER2-low tumors are gaining access to therapies that didn’t exist a few years ago. The landscape is shifting quickly enough that the old assumption of “HER2-positive equals worse” no longer holds.